TABLE 3.
VTE in CIA by Histopathology of Malignancy
| No Treatment | RBC only | ESA only | RBC and ESA | Total Patients | |
|---|---|---|---|---|---|
| Lymphoma | 126 / (346) = 36.4% | 49 /(95) = 51.6% | 4 / (7) = 57.1% | 0 /(5) = 0.0% | 179/(453) = 39.5% |
| HR = 2.24, 95% CI 1.60‐3.12, P < .001 | HR = 0.60, 95% CI 0.22‐1.64, P = .32 | ||||
| Leukemia | 90 /(182) = 49.5% | 36 / (96) = 37.5% | 2 / (3) = 66.7% | 0 /(1) = 0.0% | 128/(282) = 45.4% |
| HR = 0.79, 95% CI 0.53‐1.15, P = .22 | HR = 1.55, 95% CI 0.38‐6.29, P = .54 | ||||
| Carcinoma | 301 /(1091) = 27.6% | 57 / (147) = 38.8% | 14 / (62) = 22.6% | 3 /(27) = 11.1% | 375/(1327) = 28.3% |
| HR = 1.97, 95% CI 1.49‐2.60, P < .001 | HR = 0.58, 95% CI 0.35‐0.94, P = .029 | ||||
| Sarcoma | 159 / (251) = 63.3% | 33 /(69) = 47.8% | 11 /(16) = 68.8% | 5 /(21) = 23.8% | 208/(357) = 58.3% |
| HR = 0.67, 95% CI 0.47‐0.96, P = .031 | HR = 0.69, 95% CI 0.41‐1.16, P = .16 | ||||
| Multiple Myeloma | 89 / (204) = 43.6% | 28 / (57) = 49.1% | 1 / (11) = 9.1% | 1 /(2) = 50% | 119/(274) = 43.4% |
| HR 1.58, 95% CI 1.04‐2.41, P = .032 | HR = 0.36, 95% CI 0.09‐1.44, P = .15 |
Note: In the above table, each value listed as (x/y), x pertains to all patients who received the specified treatment who had a VTE, while y pertains to all patients who received the specified treatment.